Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
1999-07-12
2001-11-20
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S179000, C514S180000, C514S181000, C514S903000, C514S732000
Reexamination Certificate
active
06319914
ABSTRACT:
TECHNICAL FIELD
The present invention relates to novel compositions and methods for the protection of tissues, cells, and organs both in vivo and in vitro.
BACKGROUND
Degenerative diseases and aging are characterized by a broad spectrum of symptoms which vary in severity and range from individual to individual.
A common feature of degenerative disorders and diseases, trauma and the process of aging in animals is the progressive damage to cells and consequently tissues and organs. This damage may be caused by an external agent and may act in combination with internal cellular processes. Cell death may occur by necrotic or apoptotic mechanisms. For example, ischemia, which may occur as a result of stroke, heart disease or a transplantation event, arises from a cut-off in oxygen and nutritional supply to tissues which results in extensive cell damage. Treatments to minimize cell, tissue and organ damage would be helpful to ameliorate the consequences of ischemic events. Other examples where cell protection is desirable include the brain where damaged neurons and supporting structures are associated with neurodegenerative diseases that give rise to conditions such as Alzheimer's disease. In the heart, damaged muscle and endothelial cells are associated with cardiovascular disease. In bone, osteoporosis is associated with damaged osteocytes and osteoblasts. Treatments to modulate cell death associated with such conditions could be of significant benefit to an aging population.
The absence of an effective cytoprotective therapy can result in either loss of life or a general decline in the quality of life including permanent disability with high health care costs to patients, their families and the health care providers.
SUMMARY
The invention provides a method for conferring a cytoprotective effect on a population of cells that includes: providing a polycyclic phenolic compound in a physiologically acceptable formulation; and administering the formulation in an effective dose to the population of cells to confer cytoprotection.
In a preferred embodiment of the invention, a method for conferring cytoprotection in a population of cells in a subject is provided that includes: providing an effective dose of a polycyclic phenolic compound in a pharmaceutical formulation; and administering the formulation in an effective dose to the subject to confer cytoprotection.
REFERENCES:
patent: 4897389 (1990-01-01), Aroonsakal
patent: 4957909 (1990-09-01), Abou-Gharbia et al.
patent: 5002965 (1991-03-01), Ramwell et al.
patent: 5051352 (1991-09-01), Martindale et al.
patent: 5109017 (1992-04-01), Schmiesing et al.
patent: 5393763 (1995-02-01), Black
patent: 5457117 (1995-10-01), Black
patent: 5510370 (1996-04-01), Hock
patent: 5512557 (1996-04-01), Collins
patent: 5550029 (1996-08-01), Simpkins et al.
patent: 5554601 (1996-09-01), Simpkins et al.
patent: 5641790 (1997-06-01), Draper
patent: 5646137 (1997-07-01), Black et al.
patent: 5733926 (1998-03-01), Gorbach
patent: 5824672 (1998-10-01), Simpkins et al.
patent: 5843934 (1998-12-01), Simpkins
patent: 5859001 (1999-01-01), Simpkins et al.
patent: 5877169 (1999-03-01), Simpkins
patent: 5914325 (1999-06-01), Droescher et al.
patent: 5952374 (1999-09-01), Clarkson et al.
patent: 5972923 (1999-10-01), Simpkins et al.
patent: 5977096 (1999-11-01), Droescher et al.
patent: 6172056 (2001-01-01), Droescher et al.
patent: 339 579 (1989-11-01), None
patent: 0 606 661 (1994-07-01), None
patent: 0659418 A1 (1995-06-01), None
patent: 0 659 418 (1995-06-01), None
patent: 92/03049 (1992-03-01), None
patent: WO92/03049 (1992-03-01), None
patent: WO92/07855 (1992-05-01), None
patent: 92/07855 (1992-05-01), None
patent: WO92/13538 (1992-08-01), None
patent: WO 95/13076 (1993-11-01), None
patent: WO95/10513 (1995-04-01), None
patent: WO 98/43647 (1998-10-01), None
Behl et al., Biochem. Biophys. Res. Commun., 216(2), 1995, 473-82.*
HCAPLUS DN 126:70328, Green et al., Neurosci. Lett., 218(3), 1996, 165-168 (abstract).*
Huggins, Charles, et al., Chemical Structure of Steroids in relation to promotion of growth of the vagina and uterus of the hypophy sectorized rat; Journal of Experimental Medicine, vol. 100, pp. 225-243, (1954).
Nomenclature of Inorganic Chemistry: J. American Chemical Society, vol. 82, pp. 5525-5581, (1960).
Black, L. et al., Factors Affecting the Dye Exclusion Test for Cell Viability, 35:9-13 (1964).
Korenman, Stanley G., Comparative Binding Affinity of Estrogens and its Relation to Estrogenic Potency, vol. 13, pp. 163-177 (1969).
Definitive Rules for Nomenclature of Steroids: Pure and Applied Chemistry, vol. 31, pp. 285-322 (1972).
Chernayaev, G.A., et al., A Series of Optical, Structural and Isomeric Analogs of Estradiol: A Comparative Study of the Biological Activity and Affinity to Cytosol Receptor of Rabbit Uterus, The Journal of Steroid Biochemistry, vol. 6, pp 1483-1488. (1975).
Hackman, B. W., et al., “Replacement Therapy with Piperazine Oestrone Sulphate (‘Harmogen’) and Its Effect on Memory,” Current Medical Research and Opinion 4:303-306 (1976).
Perez-Polo, J. R., et al., Steroid Induction of Nerve Growth Factor Synthesis in Cell Culture; Life Sci. 21, pp. 1535-1543 (1976).
Utian, Wulf, Current Status of Menopause and Postmenopausal Estrogen Therapy; Obstetrical and Gynecological Survey, vol. 32, No. 4, pp. 193-197 (1976).
Pons, Michael, et al., Structural Requirements for Maximal Inhibitory Allosteric Effect of Estrogens and Estrogen Analogues on Glutamate Dehydrogenase, Eur. J. Biochemistry, vol. 84, pp. 257-266, (1978).
Beatty William., Gonadal Hormones and Sex Differences in Nonreproductive Behavior in Rodents: Organizational and Activational Influences; Hormones and Behavior, vol. 12, pp. 112-163 (1979).
Loy, Rebekah et al., Sexual Dimorphism in Extent of Axonal Sprouting in Rat Hippocampus, Science vol. 208, pp. 1282-1284 (1980).
Matsumoto, Akira et al., “Neuronal Plasticity in the Deafferented Hypothalamic Arcuate Nucleus of Adult Female Rats and Its Enhancement by Treatment with Estrogen,” The Journal of Comparative Neurology, vol. 197, pp. 197-205 (1981).
Nishizuka, M., et al., “Oranizational action of estrogen on synaptic pattern in the amygdala: implications for sexual differentiation of the brain”; Brain Research vol. 213, pp. 422-426 (1981).
Toran-Allerand, C. Dominique, “Gonadal Steroids and Brain Development—In Vitro Veritas?”, TINS, pp. 118-121 (May 1981).
Arvidson, Nils Gunnar, et al., “Oestrogens and anti-oestrogens show dissociation between early uterine vasular responses and uterotrophic effects in mice”, Acta Endocrinologica, vol. 100, pp. 290-294 (1982).
Barde, Yves-Alain, et al., “Purification of a neurotrophic factor from mammalian brain”, EMBO J., vol. 1, pp. 549-553 (1982).
Clark, James H., et al., “Effects of Estradol-17x on Nuclear Occupancy of the Estrogen Receptor, Stimulation of Nuclear Type II Sites and Uterine Growth”, Journal of Steroid Biochemistry, vol. 16, pp. 323-328 (1982).
Hier, Daniel B., et al., “Spatial Ability in Androgen-Deficient Men,” The New England Journal of Medicine, vol. 306, pp. 1202-1205 (1982).
Clark, James H., et al, “The Agonistic and Antagonistic Effects of Short Acting Estrogens: A Review”, Pharmacy Ther., vol. 21, pp. 429-453 (1983).
Toran-Allerand, C. Dominique, et al., “Sex Steroids and the Development of the Newborn Mouse Hypothalamus and Preoptic Area in Vitro: III. Effects of Estrogen on Dendritic Differentiation,” Developmental Brain Research vol. 7, pp. 97-101 (1983).
Namba, H., et al., “Acute administration of high doses of estrogen increases glucose utilization throughout brain”, Brain Research, vol. 291, pp. 391-394 (1984).
Collins, Aila, et al., “Psychoneuroendocrine Stress Responses and Mood as Related to the Menstrual Cycle,” Psychosomatic Medicine, vol. 47, pp. 512-527 (1985).
Gabrieli, J. D. E., et al., “The Influence of Sex Steroids on Human Nonverbal Memory Processes,” Ann. NY Academy of Sciences, vol. 444, pp. 457-459 (1985).
Papendorp, John T., “On the role of 17 Alpha-Estradiol and 17 Beta-Estradiol in the Proliferation of MCF7 and T47D-A11 Human
Gordon Katherine D.
Green Pattie S.
Simpkins James W.
Apollo BioPharmaceuticals, Inc.
Bromberg & Sunstein LLP
Delacroix-Muirheid C.
Jones Dwayne C.
LandOfFree
Cytoprotective effect of polycyclic phenolic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytoprotective effect of polycyclic phenolic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytoprotective effect of polycyclic phenolic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2600960